NOTICE OF UPGRADE

Our websites will be unavailable between the hours of AEST 4AM September 17, 2022 and AEST 11PM on date September 18, 2022

InvestoGain Australia
 

SEARCH LISTED COMPANY


Any AUS or NZ company

Browse Australian listed companies

0-9A B C D E F G H I J K L M N O P Q R S T U V W XY Z

Browse current Australian managed funds

0-9A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

SEARCH PRIVATE COMPANY


SEARCH FUNDS

Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:

SUDA PHARMACEUTICALS LTD (SUD)

Click here for free access to this company's:
ASX, Legal & CGT Status

Former (or subsequent) names

 FROMTO
AROVELLA THERAPEUTICS LIMITED25/10/2021
SUDA PHARMACEUTICALS LTD05/12/201725/10/2021
SUDA LTD07/12/201205/12/2017
EASTLAND MEDICAL SYSTEMS LTD07/12/2012

Shareholder links

Our website ranking of SUD: rating 3
(3 out of 5)
COMPANY WEBSITE:

 

REGISTRY:

Advanced Share Registry Services
110 Stirling Hwy, Nedlands WA 6009
Tel : +61 8 9389 8033
Fax : +61 8 9262 3723
RegistryWebsite RegistryEmail

Company details

ISIN: AU000000SUD7
Address: The CFO Solution Level 3 62 Lygon Street Carlton VIC 3053
Tel:  +61 8 6142 5555Fax: +61 8 9443 8858

Date first listed: 24/01/2002

Sector: Pharmaceuticals & Biotechnology Industry Group: XHJ
Activities: Developer, manufacturer and supplier of medical devices, particularly injection, infusion and blood-drawing devices

News & Events

Expand this box to read and print

name changed to Arovella Therapeutics Limited

25/10/2021

The suspension of trading in the securities of SUDA Pharmaceuticals Ltd will be lifted immediately following the release by SUD of an announcement regarding a market update.

25/06/2020

In the lead up to the company requesting a trading halt, Suda had established an independent transaction committee to assess and pursue the material licensing transaction, conducted extensive due diligence inquiries on, and an independent valuation of, the target asset, advanced negotiations of the transaction documents. ASX has now formally advised the company that there is a significant likelihood the ASX will exercise its discretion to decline Suda's application for readmission if it chooses to proceed with the proposed transaction. With ASX's current determination, it is not possible for the company to proceed with the proposed transaction. The accompanying capital raising will, accordingly, also not proceed at this time.

25/06/2020

The securities of Suda Pharmaceuticals Ltd will be suspended from quotation immediately under Listing Rule 17.2, at the request of SUD, pending the release of an announcement regarding a proposed licensing transaction and a capital raising.

05/06/2020

we understand that on or about this date the company consolidated its shares 1 for 25

22/11/2019

The suspension of trading in the securities of Suda Pharmaceuticals Ltd will be lifted immediately, following receipt of a response to an ASX Query.

17/10/2018

The company issues a response to ASX query.

17/10/2018

The securities of Suda Pharmaceuticals Ltd will be suspended from quotation immediately under Listing Rule 17.3.

17/10/2018

name changed from Suda Ltd

05/12/2017

 

Click here for free access to this company's:
ASX, Legal & CGT Status

Your comments

Please read our Terms before viewing comments.
Loading comments....  Most recent comments
Dear investogain.com.au webmaster, Good to see your posts!12/03/2023 21:27:42

Company Updates

Post your comments here

Please read our Terms before posting comments.
OMISSIONS
    You can post a comment here about this company

    Please click in the "I'm not a robot" box and enter the word/figures you see in the image that then appears.

    loading Posting your comments. Please wait...

     


     

    Click here for free access to this company's:
    ASX, Legal & CGT Status

    Directors' on-market share transactions (last 5)

    rss feeds

    Purchases Sales

    DATEDIRECTORNUMBERPRICEAMOUNT
    10/11/2020Paul Hopper234,669$0.039$9,152
    05/11/2020David Simmonds250,000$0.040$10,000
    27/10/2020Michael Baker400,000$0.042$16,800
    21/11/2019Paul Hopper200,000$0.062$12,310
    10/09/2019Paul Hopper1,000,000$0.004$4,000

    Click here for the last 20 transactions all companies

    Directors & Executives (current)

    NAMETITLEDATE OF APPT
    Paul HopperNon Exec Chairman15/05/2019
    Joseph OhayonCFO01/07/2010
    David SimmondsNon Exec Director27/03/2019
    Michael BakerExecutive Director, CEO02/01/2020
    David PhillipsExecutive Director06/04/2018
    Phillip HainsCompany Secretary

    Date of first appointment, title may have changed.

    SPECIAL NOTE: During May 2024 we are working to remove duplications in the Company Secretary role.

    Directors & Executives (former)

    NAMETITLEDATE OF APPOINTMENTDATE OF RESIGNATION
    Stephen CarterManaging Director, CEO26/10/201023/09/2019
    Michael StewartNon Exec Chairman11/06/200910/04/2018
    Ken RobsonNon Exec Director08/03/201307/08/2014
    Peter JoosteNon Exec Chairman03/07/200630/11/2012

    Date of first appointment, title may have changed.